nach oben

Neurological Sciences

Erschienen in:

04.05.2022 | Original Article

Cardiovascular autonomic dysfunction in multiple sclerosis—findings and relationships with clinical outcomes and fatigue severity

verfasst von: Łukasz Rzepiński, Monika Zawadka-Kunikowska, Julia L. Newton, Paweł Zalewski, Joanna Słomko

Erschienen in: Neurological Sciences | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study evaluates cardiovascular autonomic dysfunction (CAD) in multiple sclerosis (MS) and explores if CAD is related to clinical outcomes and fatigue severity.

Methods

A total of 53 MS patients (30 relapsing–remitting, RRMS; 23 progressive, PMS) and 30 healthy controls were evaluated. TaskForce® Monitor was used to assess impedance cardiography parameters, heart rate (HRV), and blood pressure (BPV) variability during head-up tilt test (HUTT). Expiration/inspiration (E/I) ratio was assessed in response to a deep breathing test. Fatigue severity was evaluated using Chalder Fatigue Scale (CFQ).

Results

Compared to controls, PMS patients were characterized by increased sympathetic-parasympathetic ratio at rest (p < 0.01), decreased resting values of parasympathetic parameters (high-frequency HRV, p < 0.05; E/I ratio, p < 0.001), and index of contractility (p < 0.05), whereas RRMS patients showed reduced E/I ratio (p < 0.01). Compared to RRMS group, PMS patients had higher sympathovagal ratio and lower cardiac inotropy parameters (p < 0.05). No intergroup differences were observed for cardiovascular and autonomic function test parameters after HUTT. PMS and low CFQ physical score were identified as independent predictors of sympathetic hyper-reactivity as measured with HRV. Greater disability and male sex were predictors of diastolic BP increase and reduced cardiac inotropy parameters, and older age was predictor of decreased vagal tone (E/I ratio, high-frequency HRV).

Conclusion

Cardiovascular autonomic modulation is altered in MS and highly dependent on disease variant, disability level, fatigue severity, and patients’ demographics.

Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 25:215–237. https://doi.org/10.1111/ene.13536CrossRefPubMed

Habek M (2019) Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications. Clin Auton Res 29(3):267–275. https://doi.org/10.1007/s10286-019-00605-zCrossRefPubMed

Rzepiński Ł, Zawadka-Kunikowska M, Maciejek Z et al (2019) Early clinical features, time to secondary progression, and disability milestones in Polish multiple sclerosis patients. Medicina (Kaunas) 55(6):232. https://doi.org/10.3390/medicina55060232.MedicinaCrossRef

Racosta JM, Kimpinski K (2016) Autonomic dysfunction, immune regulation, and multiple sclerosis. Clin Auton Res 26(1):23–31. https://doi.org/10.1007/s10286-015-0325-7CrossRefPubMed

Zila I, Mokra D, Kopincova J et al (2017) Vagal-immune interactions involved in cholinergic anti-inflammatory pathway. Physiol Res 66:S139–S145CrossRef

Racosta JM (2019) Autonomic nervous system dysfunction and fatigue in multiple sclerosis: common pathophysiology or spurious association? Clin Auton Res 29(3):261–262. https://doi.org/10.1007/s10286-018-0580-5CrossRefPubMed

Mincu RI, Magda LS, Florescu M et al (2015) Cardiovascular dysfunction in multiple sclerosis. Maedica (Bucur) 10(4):364–370

Studer V, Rocchi C, Motta C et al (2017) Heart rate variability is differentially altered in multiple sclerosis: implications for acute, worsening and progressive disability. Mult Scler J Exp Transl Clin 3(2):2055217317701317. https://doi.org/10.1177/2055217317701317

Low PA (1993) Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc 68(8):748–752. https://doi.org/10.1016/s0025-6196(12)60631-4CrossRefPubMed

10.

Racosta JM, Sposato LA, Morrow SA et al (2015) Cardiovascular autonomic dysfunction in multiple sclerosis: a meta-analysis. Mult Scler Relat Disord 4(2):104–111. https://doi.org/10.1016/j.msard.2015.02.002CrossRefPubMed

11.

Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed

12.

Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl 1):1–5. https://doi.org/10.1159/000367614CrossRefPubMed

13.

Adamec I, Crnošija L, Junaković A et al (2018) Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype. Clin Neurophysiol 129(8):1588–1594. https://doi.org/10.1016/j.clinph.2018.05.009CrossRefPubMed

14.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRef

15.

Kalincik T, Cutter G, Spelman T et al (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287–3298. https://doi.org/10.1093/brain/awv258CrossRefPubMed

16.

Klotz L, Havla J, Schwab N et al (2019) (2019) Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 12:1756286419836571. https://doi.org/10.1177/1756286419836571CrossRefPubMedPubMedCentral

17.

Chilcot J, Norton S, Kelly ME et al (2016) The Chalder Fatigue Questionnaire is a valid and reliable measure of perceived fatigue severity in multiple sclerosis. Mult Scler 22(5):677–684. https://doi.org/10.1177/1352458515598019CrossRefPubMed

18.

Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (1996) Assessment clinical autonomic testing report of the therapeutics and technology subcommittee of the American Academy of Neurology. Neurology 46: 873–880

19.

Fortin J, Klinger T, Wagner C et al (1998) The task force monitor–a non-invasive beat-to beat monitor for hemodynamic and autonomic function of the human body. Proc 20th Annu Int Conf IEEE Eng Med Biol Soc 66: 151–63

20.

Gratze G, Fortin J, Holler A et al (1998) A software package for non-invasive, real-time beat-to-beat monitoring of stroke volume, blood pressure, total peripheral resistance and for assessment of autonomic function. Comput Biol Med 28:121–142CrossRef

21.

Bianchi AM, Mainardi L, Meloni C et al (1997) Continuous monitoring of the sympatho-vagal balance through spectral analysis. IEEE Eng Med Biol Mag 16:64–73CrossRef

22.

Taskforce of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J 17: 354–81

23.

Parati G, Di Renzo M, Macia G (2000) How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens 18:7–19CrossRef

24.

Hilz ML, Dütsch M (2006) Quantitative studies of autonomic function. Muscle Nerve 33(1):6–20CrossRef

25.

Flachenecker P, Reiners K, Krauser M et al (2001) Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler J 7:327–334CrossRef

26.

Elenkov IJ, Wilder RL, Chrousos GP et al (2000) The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52(4):595–638PubMed

27.

Rajda C, Bencsik K, Vécsei LL et al (2002) Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J Neuroimmunol 124:93–100. https://doi.org/10.1016/s0165-5728(02)00002-4CrossRefPubMed

28.

Marrosu F, Maleci A, Cocco E et al (2007) Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Mult Scler 13:1200–1202CrossRef

29.

Hamlin N, Waldman C, Esacoff C et al (2021) Vagus nerve stimulation attenuates demyelination and accelerates remyelination in a lysolecithin-induced multiple sclerosis model. ECTRIMS Online Library http://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200835/nicole.hamlin.vagus.nerve.stimulation.attenuates.demyelination.and.accelerates.html

30.

Almeida-Santos MA, Barreto-Filho JA, Oliveira JL et al (2016) Aging, heart rate variability and patterns of autonomic regulation of the heart. Arch Gerontol Geriatr 63:1–8. https://doi.org/10.1016/j.archger.2015.11.011CrossRefPubMed

31.

Newton JL, Okonkwo O, Sutcliffe K et al (2007) Symptoms of autonomic dysfunction in chronic fatigue syndrome. QJM Int J Med 100:519–526CrossRef

32.

Herring TE, Alschuler KN, Knowles LM (2021) Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis. Mult Scler Relat Disord 54:103109. https://doi.org/10.1016/j.msard.2021.103109CrossRefPubMed

33.

KrbotSkorić M, Crnošija L, Adamec I et al (2019) Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue. Clin Auton Res 29(3):321–328. https://doi.org/10.1007/s10286-018-0563-6CrossRef

34.

Lebre AT, Mendes MF, Tilbery CP et al (2007) Relação entre fadiga e distúrbios autonômicos na esclerose múltipla [Relation between fatigue and autonomic disturbances in multiple sclerosis]. Arq Neuropsiquiatr 65: 663–8. Portuguese. https://doi.org/10.1590/s0004-282x2007000400023

35.

Niepel G, Bibani RH, Vilisaar J et al (2013) Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. Neuropharmacology 64:380–388CrossRef

36.

Flachenecker P, Rufer A, Bihler I et al (2003) Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 61(6):851–853. https://doi.org/10.1212/01.wnl.0000080365.95436.b8CrossRefPubMed

37.

Palladino R, Marrie RA, Majeed A et al (2020) Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol 77(7):820–828. https://doi.org/10.1001/jamaneurol.2020.0664CrossRefPubMed

38.

Ranadive SM, Yan H, Weikert M et al (2012) Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc 44:238–243CrossRef

39.

Mincu RI, Magda SL, Mihaila S et al (2018) Impaired cardiac function in patients with multiple sclerosis by comparison with normal subjects. Sci Rep 8(1):3300. https://doi.org/10.1038/s41598-018-21599-0CrossRefPubMedPubMedCentral

40.

Hilz MJ, Intravooth T, Moeller S et al (2015) Central autonomic dysfunction delays recovery of fingolimod induced heart rate slowing. PLoS ONE 10(7):e0132139. https://doi.org/10.1371/journal.pone.0132139CrossRefPubMedPubMedCentral

Titel: Cardiovascular autonomic dysfunction in multiple sclerosis—findings and relationships with clinical outcomes and fatigue severity
verfasst von: Łukasz Rzepiński
Monika Zawadka-Kunikowska
Julia L. Newton
Paweł Zalewski
Joanna Słomko
Publikationsdatum: 04.05.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 8/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06099-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study

A snapshot of emergency neurology management in the Lombardy Region, Italy

The prediction effects of thyroid function in the severity of Guillain-Barré syndrome

COVID-19-associated severe mono-hemispheric encephalitis in a young infant

Dolichoectasia: a brain arterial disease with an elusive treatment